Physician profile
Sofija A Rak
NPI 1225359557
$3,163.07
in general payments reported to CMS, 2019-2025
35 companies · $302 in 2025
The $302 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $435 · 2020: $289 · 2021: $493 · 2022: $529 · 2023: $585 · 2024: $530 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,417.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,417.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $501.28 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $403.19 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Pfizer INC. | $293.40 | 2019-2025 | |
| Astellas Pharma US INC | $271.11 | 2019-2024 | Veozah, Myrbetriq |
| Abbott Laboratories | $227.67 | 2022-2025 | Freestyle Libre 3 |
| Eisai INC. | $182.46 | 2019-2025 | |
| Abbvie INC. | $174.93 | 2020-2025 | |
| Astrazeneca Pharmaceuticals Lp | $160.42 | 2019-2025 | Farxiga, Breztri |
| Vivus LLC | $144.60 | 2019-2022 | |
| Lilly USA, LLC | $132.62 | 2020-2024 | Zepbound, Mounjaro, Jardiance |
| Sumitomo Pharma America, INC. | $66.29 | 2023-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.66 | 2024 | |
| Exact Sciences Corporation | $54.10 | 2023-2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $53.17 | 2023-2025 | Vaxneuvance, Gardasil 9, Capvaxive |
| Cranial Technologies, INC | $35.88 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $35.09 | 2019 | |
| Almatica Pharma LLC | $33.82 | 2021-2022 | |
| Sanofi Pasteur INC. | $32.18 | 2023 | |
| Coloplast Corp | $29.02 | 2020 | |
| Currax Pharmaceuticals LLC | $25.53 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.36 | 2019 | |
| Idorsia Pharmaceuticals US INC | $19.72 | 2022 | |
| Daiichi Sankyo INC. | $19.72 | 2023 | Injectafer |
| Gilead Sciences, INC. | $19.12 | 2019 | |
| Hologic Sales and Service, LLC | $18.20 | 2024 | Aptima |
| Horizon Therapeutics Plc | $17.55 | 2020 | |
| Ibsa Pharma INC. | $16.85 | 2020 | |
| Sunovion Pharmaceuticals INC. | $16.40 | 2021 | |
| Dermira, INC. | $16.21 | 2019 | |
| Amarin Pharma, INC. | $15.44 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.57 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.89 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.94 | 2019 | |
| Adlon Therapeutics L.P. | $11.93 | 2021 | |
| Nalpropion Pharmaceuticals LLC | $11.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sofija Rak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.